Chinese Journal of Antituberculosis ›› 2026, Vol. 48 ›› Issue (3): 335-341.doi: 10.19982/j.issn.1000-6621.20250386
• Original Articles • Previous Articles Next Articles
Zhu Qingdong1, Zhao Chunyan1,2, Huang Xuewen1,2, Huang Aichun1, Zeng Chunmei1, Xu Chaoyan1, Lan Yanqun1, Song Chang1,2(
)
Received:2025-09-24
Online:2026-03-10
Published:2026-03-06
Contact:
Song Chang
E-mail:songchang2022@163.com
Supported by:CLC Number:
Zhu Qingdong, Zhao Chunyan, Huang Xuewen, Huang Aichun, Zeng Chunmei, Xu Chaoyan, Lan Yanqun, Song Chang. The application value of nanopore sequencing in the diagnosis of tuberculous serous effusion and screening for coinfections[J]. Chinese Journal of Antituberculosis, 2026, 48(3): 335-341. doi: 10.19982/j.issn.1000-6621.20250386
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20250386
| 特征 | 合计(53例) | 结核组(26例) | 非结核组(27例) | 统计检验值 | P值 |
|---|---|---|---|---|---|
| 性别[例(构成比,%)] | χ2=0.053 | 0.819 | |||
| 男性 | 39(73.6) | 20(76.9) | 19(70.4) | ||
| 女性 | 14(26.4) | 6(23.1) | 8(29.6) | ||
| 年龄(岁, | 56.21±18.24 | 51.08±19.33 | 61.15±15.94 | t=2.065 | 0.044 |
| 体质量指数(kg/m2, | 21.32±3.15 | 20.56±3.34 | 22.06±2.83 | t=1.754 | 0.086 |
| 合并症[例(发生率,%)] | |||||
| 非结核分枝杆菌感染 | 2(3.8) | 0(0.0) | 2(7.4) | χ2=2.001 | 0.157 |
| 恶性肿瘤 | 8(15.1) | 2(7.7) | 6(22.2) | χ2=2.182 | 0.140 |
| 高血压 | 8(15.1) | 5(19.2) | 3(11.1) | χ2=0.681 | 0.409 |
| 糖尿病 | 3(5.7) | 2(7.67) | 1(3.7) | χ2=0.395 | 0.530 |
| 肝炎 | 1(1.9) | 0(0.0) | 1(3.7) | χ2=0.981 | 0.322 |
| HIV感染 | 6(11.3) | 3(11.5) | 3(11.1) | χ2=0.002 | 0.961 |
| 实验室指标 | 合计(53例) | 结核组(26例) | 非结核组(27例) | 统计检验值 | P值 |
|---|---|---|---|---|---|
| CD3+[个/μl, M(Q1,Q3)] | 780(541,1186) | 775(538,1187) | 794(607,1174) | Z=-0.552 | 0.590 |
| CD4+[个/μl, M(Q1,Q3)] | 402(308,614) | 372(288,619) | 405(331,576) | Z=-0.552 | 0.587 |
| CD8+[个/μl, M(Q1,Q3)] | 279(182,455) | 223(166,430) | 318(190,521) | Z=-1.005 | 0.319 |
| CD4+/CD8+[M(Q1,Q3)] | 1.53(1.08,2.25) | 1.51(1.30,2.63) | 1.55(0.99,2.03) | Z=1.041 | 0.302 |
| 白细胞计数[109/L, M(Q1,Q3)] | 6.4(5.5,8.5) | 6.3(5.7,8.9) | 6.5(5.1,7.8) | Z=1.014 | 0.315 |
| 红细胞计数(1012/L, | 3.98±0.94 | 3.99±0.96 | 3.96±0.95 | t=-0.146 | 0.884 |
| 血红蛋白(g/L, | 107.60±24.13 | 107.88±23.22 | 107.33±25.41 | t=-0.083 | 0.935 |
| 血小板计数(109/L, | 312.47±130.64 | 322.50±123.61 | 302.81±138.73 | t=-0.546 | 0.588 |
| 中性粒细胞[109/L, M(Q1,Q3)] | 4.4(3.6,6.3) | 4.6(3.7,6.4) | 4.4(3.5,6.2) | Z=0.747 | 0.460 |
| 淋巴细胞[109/L, M(Q1,Q3)] | 1.1(0.8,1.4) | 1.2(0.9,1.5) | 1.0(0.8,1.4) | Z=1.210 | 0.229 |
| 单核细胞[109/L, M(Q1,Q3)] | 0.5(0.4,0.7) | 0.5(0.4,0.7) | 0.5(0.4,0.6) | Z=0.605 | 0.546 |
| 嗜酸性粒细胞[109/L, M(Q1,Q3)] | 0.08(0.05,0.23) | 0.08(0.04,0.17) | 0.08(0.06,0.24) | Z=-0.480 | 0.637 |
| 嗜碱性粒细胞[109/L, M(Q1,Q3)] | 0.03(0.02,0.04) | 0.03(0.02,0.04) | 0.04(0.02,0.05) | Z=0.080 | 0.942 |
| C反应蛋白[mg/L, M(Q1,Q3)] | 27.6(5.0,68.3) | 31.9(8.4,69.4) | 20.2(5.0,60.7) | Z=0.569 | 0.569 |
| 血红细胞沉降率[mm/1h, M(Q1,Q3)] | 55.0(27.0,100.0) | 55.0(33.0,72.0) | 56.5(25.5,102.5) | Z=-0.044 | 0.972 |
| 检测方法 | 最终诊断(例) | 敏感度 (%,95%CI) | 特异度 (%,95%CI) | 阳性预测值 (%,95%CI) | 阴性预测值 (%,95%CI) | Kappa值 (95%CI) | AUC (95%CI) | |
|---|---|---|---|---|---|---|---|---|
| 结核 (26例) | 非结核 (27例) | |||||||
| 纳米孔测序 | 73.1 (51.9~87.6) | 100.0 (84.5~100.0) | 100.0 (79.1~100.0) | 79.4 (61.6~90.7) | 0.734 (0.558~0.910) | 0.860 (0.748~0.972) | ||
| 阳性 | 19 | 0 | ||||||
| 阴性 | 7 | 27 | ||||||
| 抗酸染色 | 11.5 (3.0~31.3) | 100.0 (84.5~100.0) | 3/3 (31.0~100.0) | 54.0 (39.5~67.9) | 0.117 (0.010~0.244) | 0.560 (0.402~0.718) | ||
| 阳性 | 3 | 0 | ||||||
| 阴性 | 23 | 27 | ||||||
| 培养 | 30.8 (15.1~51.9) | 100.0 (84.5~100.0) | 8/8 (59.8~100.0) | 60.0 (44.4~73.9) | 0.312 (0.124~0.500) | 0.660 (0.508~0.812) | ||
| 阳性 | 8 | 0 | ||||||
| 阴性 | 18 | 27 | ||||||
| DNA检测 | 34.6 (17.9~55.6) | 100.0 (84.5~100.0) | 9/9 (62.9~100.0) | 61.4 (45.5~75.3) | 0.350 (0.156~0.544) | 0.660 (0.508~0.812) | ||
| 阳性 | 9 | 0 | ||||||
| 阴性 | 17 | 27 | ||||||
| Xpert | 34.6 (17.9~55.6) | 100.0 (84.5~100.0) | 9/9 (62.9~100.0) | 61.4 (45.5~75.3) | 0.350 (0.156~0.544) | 0.673 (0.525~0.821) | ||
| 阳性 | 9 | 0 | ||||||
| 阴性 | 17 | 27 | ||||||
| 结核抗体检测 | 46.2 (27.1~66.3) | 81.5 (61.3~93.0) | 70.6 (44.0~88.6) | 61.1 (43.5~76.4) | 0.278 (0.035~0.521) | 0.627 (0.474~0.781) | ||
| 阳性 | 12 | 5 | ||||||
| 阴性 | 14 | 22 | ||||||
| [1] | Mortazavi-Moghaddam SG, Sharifzadeh GR, Rezvani MR. Status of Exudative Pleural Effusion in Adults of South Khorasan Province, Northeast Iran: Pleural Tuberculosis Tending toward Elderly. Iran J Med Sci, 2016, 41(4): 322-327. |
| [2] |
Isiguzo G, Du Bruyn E, Howlett P, et al. Diagnosis and Management of Tuberculous Pericarditis: What Is New? Curr Cardiol Rep, 2020, 22(1): 2. doi:10.1007/s11886-020-1254-1.
URL pmid: 31940097 |
| [3] | 朱庆东, 王琦, 宋畅, 等. 高通量测序技术在结核病诊断和耐药检测中的应用进展. 新发传染病电子杂志, 2024, 9(5): 78-82. doi:10.19871/j.cnki.xfcrbzz.2024.05.015. |
| [4] | Chen Q, Yi J, Liu Y, et al. Clinical diagnostic value of targeted next-generation sequencing for infectious diseases (Review). Mol Med Rep, 2024, 30(3): 153. doi:10.3892/mmr.2024.13277. |
| [5] |
van Dijk EL, Jaszczyszyn Y, Naquin D, et al. The Third Revolution in Sequencing Technology. Trends Genet, 2018, 34(9): 666-681. doi:10.1016/j.tig.2018.05.008.
URL pmid: 29941292 |
| [6] |
Wang Y, Zhao Y, Bollas A, et al. Nanopore sequencing technology, bioinformatics and applications. Nat Biotechnol, 2021, 39(11): 1348-1365. doi:10.1038/s41587-021-01108-x.
URL pmid: 34750572 |
| [7] | 中华医学会呼吸病学分会胸膜与纵隔疾病学组(筹). 胸腔积液诊断的中国专家共识. 中华结核和呼吸杂志, 2022, 45(11): 1080-1096. doi:10.3760/cma.j.cn112147-20220511-00403. |
| [8] |
Chen Y, Ling Y, Xu X, et al. Diagnostic Utility of Nanopore Sequencing for Tuberculous Serous Effusions. Infect Drug Resist, 2025, 18: 3661-3670. doi:10.2147/IDR.S524986.
URL pmid: 40718371 |
| [9] | 中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 结核与肺部疾病杂志, 2024, 5(4): 376-378. doi:10.19983/j.issn.2096-8493.2024022. |
| [10] | Ebrahimzadeh A, Pagheh AS, Mousavi T, et al. Serosal membrane tuberculosis in Iran: A comprehensive review of evidences. J Clin Tuberc Other Mycobact Dis, 2023, 31: 100354. doi:10.1016/j.jctube.2023.100354. |
| [11] | 赵春艳, 宋畅, 宋树林, 等. 纳米孔测序检测痰液样本在肺结核诊断中的应用. 中国临床医生杂志, 2024, 52(4): 413-416. doi:10.3969/j.issn.2095-8552.2024.04.009. |
| [12] | 朱庆东, 宋畅, 赵春艳, 等. 纳米孔测序检测肺部组织样本在痰涂片阴性肺结核中的诊断价值. 临床肺科杂志, 2025, 30(6): 857-861. doi:10.3969/j.issn.1009-6663.2025.06.008. |
| [13] | 闫晓婧, 王宇津, 王隽, 等. 纳米孔测序技术对涂阴肺结核患者诊断价值的多中心临床研究. 中国防痨杂志, 2025, 47(2): 169-174. doi:10.19982/j.issn.1000-6621.20240481. |
| [14] | McIntyre S, Warner J, Rush C, et al. Antibodies as clinical tools for tuberculosis. Front Immunol, 2023, 14: 1278947. doi:10.3389/fimmu.2023.1278947. |
| [15] | Zhao CY, Song C, Lin YR, et al. The diagnostic value of third-generation nanopore sequencing in non-tuberculous mycobacterial infections. Front Cell Infect Microbiol, 2025, 15: 1557079. doi:10.3389/fcimb.2025.1557079. |
| [16] |
Chen J, Xu F. Application of Nanopore Sequencing in the Diagnosis and Treatment of Pulmonary Infections. Mol Diagn Ther, 2023, 27(6): 685-701. doi:10.1007/s40291-023-00669-8.
URL pmid: 37563539 |
| [17] |
Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol, 2021, 19(12): 759-773. doi:10.1038/s41579-021-00582-z.
URL pmid: 34168328 |
| [18] | Otto M. Staphylococcus epidermidis-the ‘accidental’ pathogen. Nat Rev Microbiol, 2009, 7(8): 555-567. doi:10.1038/nrmicro2182. |
| [19] | Hosseini M, Shakerimoghaddam A, Ghazalibina M, et al. Aspergillus coinfection among patients with pulmonary tuberculosis in Asia and Africa countries; A systematic review and meta-analysis of cross-sectional studies. Microb Pathog, 2020, 141: 104018. doi:10.1016/j.micpath.2020.104018. |
| [1] | Shu Wei, Liu Yuhong. Interpretation of research and innovation part of the WHO Global Tuberculosis Report 2025 [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 307-312. |
| [2] | Wang Jing, Jing Wei, Li Weiwen, Zhu Qingdong, Pang Yu, Chu Naihui, Nie Wenjuan. Clinical cohort analysis of the efficacy and safety of extended-course bedaquiline in patients with multidrug-resistant/rifampicin-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 313-319. |
| [3] | Zhang Yujie, Zhou Jie, Wang Yun, Fan Lin. Evaluation of diagnostic value of novel blood-derived biomarkers for active pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 320-328. |
| [4] | Hou Tianyong, Ren Liping, Li Jingying, Wang Jianwei, Fan Shuhui, Wu Yuanming, Wang Quanhong, Ding Weimin. Clinical application value of combined molecular biology testing with bronchoalveolar lavage fluid (BALF) for diagnosing smear-negative pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 329-334. |
| [5] | Jiao Xiaoke, Tian Yuan, Xiang Jingling, Nie Wenjuan, Pang Yu, Wang Jing. Analysis of factors influencing disability and mortality in HIV-negative tuberculous meningitis patients from 2011 to 2023 [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 342-348. |
| [6] | Wei Liuying, Wu Xingxing, Huang Lianpiao, Zeng Chunmei, Zhao Chunyan, Song Chang, Nie Wenjuan, Pei Jie, Wei Xiaoying, Huang Aichun, Zhu Qingdong, Xie Zhouhua, Huang Xianzhen. Analysis of the application effect of compound balanced nutrition powder in anti-tuberculosis treatment on multidrug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 349-355. |
| [7] | Xu Liang, Dai Enuo, Yang Yongrui, Ruan Wenkai, Li Jianlong, Dang Rongpan, An Huigang, Zhao Wentao, Li Zhaofei, Zhao Yingxin, Li Ying, Sun Jianmin, Tan Hongdong. Observation on the effect of traditional Chinese medicine syndrome differentiation and treatment combined with standard anti-tuberculosis regimen on postoperative rehabilitation in patients with spinal tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 356-365. |
| [8] | Gao Yan, Peng Yingjie, Ge Xiao, Xu Jian, Liu Xiaohua, Liu Jinlong, Wang Yuanyuan. Screening and identification of iron death-related gene MT1G in tuberculosis based on bioinformatics [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 366-376. |
| [9] | Gu Yuhong, Liu Zengwei, Wu Xiaoying, He Liqian, Zhang Yahui, Wu Guifeng. Analysis of the screening effectiveness and influencing factors of tuberculin skin test and interferon-gamma release assays for close contacts in schools: A retrospective real-world study [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 377-385. |
| [10] | Guo Huixin, Wu Zhuhua, Chen Yanmei, Yu Meiling, Peng Kehao, Xu Liuyue, Zhang Jianhui, Chen Xunxun. Investigation and analysis of biosafety status in tuberculosis laboratories of 138 tuberculosis prevention and control institutions in Guangdong Province [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 386-393. |
| [11] | Cao Hong, Qian Bing, Zhao Kefu, Chen Lili, He Yuqin, Wu Jinju, Chen Shuangshuang, Xu Rui, Zhao Cunxi. Analysis of characteristics of pulmonary tuberculosis patients aged 60 and above in Hefei City, 2015—2024 [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 394-404. |
| [12] | Zhang Jian, Chen Bin, Zhang Mingwu, Qin Jiasheng, Song Yufang, Li Xuejing, Wang Wei. Analysis of the dynamics and influencing factors of latent tuberculosis infection in a rural elderly population in Changxing County [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 405-412. |
| [13] | Meng Qiuyue, Rong Ningning, Liu Yadong, Yang Haixia, Ma Mingli. Progress in interventions to improve treatment adherence among patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 413-418. |
| [14] | Pharmaceutical Professional Branch of Chinese Antituberculosis Association. Expert consensus on therapy and drug monitoring clinical application of anti-tuberculosis drug (updated in 2025) [J]. Chinese Journal of Antituberculosis, 2026, 48(2): 167-187. |
| [15] | Fu Xuwen, He Weiyaozhen, Li Xiang. Imaging manifestations of male reproductive system tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(2): 188-196. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.